National Institutes of Health
Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) is a funding opportunity from National Institutes of Health, closing July 2, 2027.
Overview
This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be…